Literature DB >> 21054940

Immunogenicity and immunomodulatory properties of umbilical cord lining mesenchymal stem cells.

Tobias Deuse1, Mandy Stubbendorff, Karis Tang-Quan, Neil Phillips, Mark A Kay, Thomas Eiermann, Thang T Phan, Hans-Dieter Volk, Hermann Reichenspurner, Robert C Robbins, Sonja Schrepfer.   

Abstract

We here present an immunologic head-to-head comparison between human umbilical cord lining mesenchymal stem cells (clMSCs) and adult bone marrow MSCs (bmMSCs) from patients >65 years of age. clMSCs had significantly lower HLA class I expression, higher production of tolerogenic TGF-β and IL-10, and showed significantly faster proliferation. In vitro activation of allogeneic lymphocytes and xenogeneic in vivo immune activation was significantly stronger with bmMSCs, whereas immune recognition of clMSCs was significantly weaker. Thus, bmMSCs were more quickly rejected in immunocompetent mice. IFN-γ at 25 ng/ml increased both immunogenicity by upregulation of HLA class I/ HLA-DR expression and tolerogenicity by increasing intracellular HLA-G and surface HLA-E expression, augmenting TGF-β and IL-10 release, and inducing indoleamine 2,3-dioxygenase (IDO) expression. Higher concentrations of IFN-γ (>50 ng/ml) further enhanced the immunosuppressive phenotype of clMSCs, more strongly downregulating HLA-DR expression and further increasing IDO production (at 500 ng/ml). The net functional immunosuppressive efficacy of MSCs was tested in mixed lymphocyte cultures. Although both clMSCs and bmMSCs significantly reduced in vitro immune activation, clMSCs were significantly more effective than bmMSCs. The veto function of both MSC lines was enhanced in escalating IFN-γ environments. In conclusion, clMSCs show a more beneficial immunogeneic profile and stronger overall immunosuppressive potential than aged bmMSCs.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21054940     DOI: 10.3727/096368910X536473

Source DB:  PubMed          Journal:  Cell Transplant        ISSN: 0963-6897            Impact factor:   4.064


  93 in total

1.  Hepatocyte Growth Factor Gene-Modified Mesenchymal Stem Cells Augment Sinonasal Wound Healing.

Authors:  Jing Li; Chun-Quan Zheng; Yong Li; Chen Yang; Hai Lin; Hong-Gang Duan
Journal:  Stem Cells Dev       Date:  2015-04-30       Impact factor: 3.272

2.  Meeting report of the first conference of the International Placenta Stem Cell Society (IPLASS).

Authors:  O Parolini; F Alviano; A G Betz; D W Bianchi; C Götherström; U Manuelpillai; A L Mellor; R Ofir; P Ponsaerts; S A Scherjon; M L Weiss; S Wolbank; K J Wood; C V Borlongan
Journal:  Placenta       Date:  2011-05-14       Impact factor: 3.481

Review 3.  Stem cells for the cell and molecular therapy of type 1 diabetes mellitus (T1D): the gap between dream and reality.

Authors:  Riccardo Calafiore; Giuseppe Basta
Journal:  Am J Stem Cells       Date:  2015-03-15

4.  Mesenchymal stem cells in preclinical cancer cytotherapy: a systematic review.

Authors:  Ioannis Christodoulou; Maria Goulielmaki; Marina Devetzi; Mihalis Panagiotidis; Georgios Koliakos; Vassilis Zoumpourlis
Journal:  Stem Cell Res Ther       Date:  2018-12-07       Impact factor: 6.832

5.  Bone Marrow Stromal Cells Associated with Poly L-Lactic-Co-Glycolic Acid (PLGA) Nanofiber Scaffold Improve Transected Sciatic Nerve Regeneration.

Authors:  Gholamreza Kaka; Jamshid Arum; Seyed Homayoon Sadraie; Asgar Emamgholi; Alireza Mohammadi
Journal:  Iran J Biotechnol       Date:  2017-09-27       Impact factor: 1.671

6.  Comparative analysis of human mesenchymal stem cells from fetal-bone marrow, adipose tissue, and Warton's jelly as sources of cell immunomodulatory therapy.

Authors:  Qiushi Wang; Qiaoni Yang; Zhe Wang; Haixia Tong; Liangyan Ma; Yi Zhang; Fengping Shan; Yiming Meng; Zhengwei Yuan
Journal:  Hum Vaccin Immunother       Date:  2016       Impact factor: 3.452

Review 7.  The therapeutic potential, challenges and future clinical directions of stem cells from the Wharton's jelly of the human umbilical cord.

Authors:  Ariff Bongso; Chui-Yee Fong
Journal:  Stem Cell Rev Rep       Date:  2013-04       Impact factor: 5.739

8.  Mesenchymal stromal cell characteristics vary depending on their origin.

Authors:  Heike Wegmeyer; Ann-Marie Bröske; Mathias Leddin; Karin Kuentzer; Anna Katharina Nisslbeck; Julia Hupfeld; Kornelius Wiechmann; Jennifer Kuhlen; Christoffer von Schwerin; Carsten Stein; Saskia Knothe; Jürgen Funk; Ralf Huss; Markus Neubauer
Journal:  Stem Cells Dev       Date:  2013-06-22       Impact factor: 3.272

9.  Comparative Analysis of the Immunomodulatory Properties of Equine Adult-Derived Mesenchymal Stem Cells().

Authors:  Danielle D Carrade; Michael W Lame; Michael S Kent; Kaitlin C Clark; Naomi J Walker; Dori L Borjesson
Journal:  Cell Med       Date:  2012-01-01

10.  Cord lining-mesenchymal stem cells graft supplemented with an omental flap induces myocardial revascularization and ameliorates cardiac dysfunction in a rat model of chronic ischemic heart failure.

Authors:  Shera Lilyanna; Eliana C Martinez; Thang D Vu; Lieng H Ling; Shu U Gan; Ai L Tan; Thang T Phan; Theo Kofidis
Journal:  Tissue Eng Part A       Date:  2013-02-28       Impact factor: 3.845

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.